Date Reviewed | 11/13/2023 |
Subject | Diagnosis and Treatment of Group-A Streptococcal Pharyngitis in Adults and Children |
Patient Population | Adults and children presenting with sore throat |
Rationale | Sore throat is a common presenting complaint in Urgent Care. The overwhelming majority of these patients have viral pharyngitis or non-infectious cause of sore throat with a very low pretest probability for streptococcal disease. For this reason, not all patients need rapid streptococcal antigen testing. Similarly, most patients do not require antibiotic treatment unless there is a high likelihood they have streptococcal pharyngitis. With greater emphasis being placed on Antibiotic Stewardship and curtailing the prescribing of unnecessary antibiotics for viral disease, this guideline makes recommendations for appropriate testing and treatment of patients with sore throat in the Urgent Care setting. |
Introduction | Sore throat is one of the most common complaints seen in emergency medicine and Urgent Care. Although many patients
|
Key Points for Urgent Care |
|
Discussion | One of the most important points when considering treatment for an exudative pharyngitis is not treatment to cure the disease of streptococcal pharyngitis but to provide symptom relief, prevent transmission to others, and prevent complications, the most serious of which are peritonsillar or retropharyngeal abscess and rheumatic fever, especially in the pediatric population. These complications only occur in the US in a small number of patients. Treatment of uncomplicated streptococcal pharyngitis with antibiotics only shortens the course of illness by hours to 2 days, and many cases go undetected and improve spontaneously. Most patients will improve in 3-5 days without treatment (Brink). The use of antibiotics for all sore throats without testing or with negative testing is inappropriate, potentially dangerous, and contributes to the worldwide problem of antibiotic resistance. Clinicians should prescribe antibiotics to only those patients with a high likelihood of GAS who test positive for the infection. Treating a patient for GAS without a conclusively positive test may lead to over 40% of adult patients being prescribed antibiotics unnecessarily (Mustafa). |
Additional References |
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of Mustafa Z, Ghaffari M. Diagnostic Methods, Clinical Guidelines, and Antibiotic Treatment for Group A Streptococcal Pharyngitis: A Narrative Review. Front Cell Infect Microbiol 10:563627. Ellis C, Camacho-Walsh M, AGREE Appraisal of Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Advanced Emergency Nursing Journal 37(1):p 34-41, January/March 2015. Brink WR, Rammelkamp CH Jr, Denny FW, Wannamaker LW. Effect in penicillin and aureomycin on the natural course of streptococcal tonsillitis and pharyngitis. Am J Med. 1951 Mar;10(3):300-8. doi: 10.1016/0002-9343(51)90274-4. PMID: 14819035. Ebell, M, Diagnosis of Streptococcal Pharyngitis. Am Fam Physician. 2014;89(12):976-977 Green MD, Beall B, et. al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA, Journal of Antimicrobial Chemotherapy, Volume 57, Issue 6, June 2006, Pages 1240–1243, https://doi.org/10.1093/jac/dkl101 Principi, N., Bianchini, S., Baggi, E. et al. No evidence for the effectiveness of systemic corticosteroids in acute pharyngitis, community-acquired pneumonia and acute otitis media. Eur J Clin Microbiol Infect Dis 32, 151–160 (2013). https://doi.org/10.1007/s10096-012-1747-y Sadeghirad B, Siemieniuk R A C, Brignardello-Petersen R, Papola D, Lytvyn L, Vandvik P O et al. Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomized trials BMJ 2017; 358:j3887 doi:10.1136/bmj.j3887 |
Reviewers | Tracey Q. Davidoff, MD, FCUCM and Cesar Mora Jaramillo, MD FAAFP FCUCM |
Attachments | See below |
Figure 1. Centor Criteria for sore throat (1981)
Centor Symptom | Point |
Tonsillar exudates | 1 |
Swollen, tender, anterior cervical lymph nodes | 1 |
Lack of cough | 1 |
Fever or history of fever | 1 |
Higher scores translate to a higher likelihood of streptococcal pharyngitis. Score of 1 with a 2.5% probability, and score of 4 with 56% probability.
Figure 2. McIsaac or Modified Centor Score (1998)
McIsaac Symptom | Point |
Tonsillar swelling or exudate | 1 |
Tender anterior cervical adenopathy | 1 |
No cough | 1 |
Temperature >38°C | 1 |
Age 3-14 | 1 |
Age 15-44 | 0 |
Age > 45 | -1 |
Highest score 4 associated with an 83.1% risk of streptococcal pharyngitis
Figure 3. FeverPAIN Score (2013)
Symptom | Point |
Fever in last 24 hours | 1 |
Absence of cough or coryza | 1 |
Symptoms for < 3 days | 1 |
Purulent tonsils | 1 |
Severe tonsil inflammation | 1 |
Interpretation:
Table 4. Antibiotic Treatment Choices for Confirmed Group A Streptococcal Pharyngitis
Drug, Route | Children’s Dosage | Adult Dosage | Duration | Recommendation Strength, Quality of Evidence |
No Penicillin Allergy: | ||||
Penicillin V, oral | 250 mg BID-TID | 250 mg QID or 500 mg BID | 10 days | Strong, high |
Amoxicillin, oral | 50 mg/kg once daily, max. 1000 mg 25 mg/kg twice daily, max. 1000 mg | 500 mg BID | 10 days | Strong, high |
Benzathine penicillin G, IM | < 27 kg, 600,000 Units; > 27 kg, 1.2 mUnits | 1.2 mUnits | Once | Strong, high |
Penicillin Allergy | ||||
Cephalexin, oral | 20 mg/kg/dose BID, max 1000 mg per day | 500 mg BID | 10 days | Strong, high |
Cefadroxil, oral | 30 mg/kg/dose BID, max 1000 mg per day | 500 mg BID | 10 days | Strong, high |
Clindamycin, oral | 7 mg/kg/dose TID, max 900 mg/day | 300 mg BID | 10 days | Strong, moderate |
Azithromycin*, oral | 12 mg/kg once daily, max 500 mg Or 12 mg/kg once, followed by 6 mg/kg day 2-5, max 500 mg/dose | 500 mg daily Or 500 mg day 1, then 250 mg day 2-5 | 5 days | Strong, moderate |
Clarithromycin*, oral | 7.5 mg/kg/dose BID, max 250 mg/dose | 250 mg BID | 10 days | Strong, moderate |
*Note increasing resistance to macrolides in some areas may not be as effective. Check antibiograms in your area.